Isis, Biogen Idec Ink Antisense Drug-Development Partnership
December 13, 2012
Isis, Biogen Idec Ink Antisense Drug-Development Partnership
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Pfizer Aims to Head Off Court Hearing over Isis, Santaris Patent Dispute
April 11, 2013 / Gene Silencing News - Isis, Roche Partner on Huntington’s Disease Drug Program
April 11, 2013 / Gene Silencing News - Pfizer, Shire Pulled into Isis Suit Against Santaris with Subpoena Dispute
March 14, 2013 / Gene Silencing News - FDA Gives Green Light to Isis' Cholesterol Drug Kynamro, Marking Milestone for Oligo Drug Field
January 31, 2013 / Gene Silencing News - Alnylam Forms Alliance with Genzyme in ATTR, Adds Another Notch to Partnership Belt
October 25, 2012 / Gene Silencing News